Apotex's Planned Angiomax Generic Spurs Patent Suit

Law360, Washington (May 2, 2013, 7:57 PM EDT) -- The Medicines Co. hit generic-drug maker Apotex Inc. with an infringement suit in New Jersey federal court on Tuesday, claiming the company's application to market a generic version of the blood thinner Angiomax violates two of its patents.

Apotex notified The Medicines Co. it had filed an abbreviated new drug application with the U.S. Food and Drug Administration to market its own version of the bivalirudin intravenous injection, but The Medicines Co. maintains the generic company hasn't proven their product won't infringe the patents-in-suit.

“Apotex admits...
To view the full article, register now.